

UTI treatment Market to grow over USD 9.89 Billion revenue with stable CAGR of 3.6% by 2023

UTI treatment Market by Drug Class (Quinolones, Aminoglycosides, β -lactam, Azoles and Others), by Clinical Indications, by End User - Forecast to 2023

PUNE, MAHARASHTRA, INDIA, June 9, 2017 /EINPresswire.com/ -- Market Highlights



Major key Players include Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy's Laboratories Ltd., Johnson & Johnson GlaxoSmithKline "

Market Research Future

The [global UTI Treatment market](#) has been evaluated as a moderate growth market with a sustainable growth. With respect to market Pfizer accounted for the largest market share followed by GlaxoSmithKline.

The development pipeline for UTI drugs is poor due to the excellent efficacy and efficiency of Quinolones. The share of β -lactam antibiotics has declined due to development of resistance. The highest prevalence of UTI infections occur in the intensive care units followed by general wards of hospitals which comes as a shock and irony. Loss of patents and growing penetration of generics has resulted

in withdrawal of many players from the market. Thus new drug development having substantial advantage over the present drugs is the need of the hour, which becomes more acute due to the detection of resistance to the quinolone class of antibacterial. The other market trend includes bias towards combination therapy to avoid drug resistance and improve clinical outcomes.

Taking all these factors into consideration, the Global UTI treatment drugs market had reached around \$ 9.89 billion in 2023 from \$ 8 billion in 2016 growing at a CAGR of 3.6%.

Key players of Global UTI treatment Market:

- Bayer AG,
- Novartis AG,
- Pfizer Inc.,
- F. Hoffmann-La Roche Ltd,
- AstraZeneca,
- Cipla Inc.,
- Dr. Reddy's Laboratories Ltd.,
- Johnson & Johnson GlaxoSmithKline

•Others.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/3146

Segments:

The Global UTI treatment Market is segmented

On the basis of drug class which comprises of quinolones, aminoglycosides, β -lactam, azoles and others.

On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis.

On the basis of end users the market is segmented into hospitals and self-administered.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on "[Global UTI treatment Market Research Report- Global Forecast To 2023](#)"

Browse full report @ <https://www.marketresearchfuture.com/reports/uti-treatment-market-3146>

U.S. leads the market for UTI treatment followed by Europe. However Europe leads the rate of hospital admissions even though the U.S. spends far greater on healthcare. However there has been huge changes in the regulatory environment of the U.S. which has threatened the market for UTI treatment. The regulatory changes in the U.S. such as implementation of Affordable Care Act and Hospital Readmissions Reduction Program coupled with Medicare initiative to penalize unnecessary patient readmissions is expected to slightly hamper the U.S UTI treatment market

Table of Content

- 1 Introduction
 - 1.1 Definition
 - 1.2 Scope Of Study
 - 1.3 Research Objective
 - 1.4 Assumptions & Limitations
 - 1.5 Market Structure:
- 2 Research Methodology
 - 2.1 Research Process
 - 2.2 Primary Research
 - 2.3 Secondary Research
- 3 Market Dynamics
 - 3.1 Drivers
 - 3.2 Restraints
 - 3.3 Opportunities

- 3.4 Challenges
 - 3.5 Macroeconomic Indicators
 - 4 Market Factor Analysis
 - 4.1 Porter's Five Forces Model
 - 4.1.1 Bargaining Power Of Suppliers
 - 4.1.2 Bargaining Power Of Customer
 - 4.1.3 Intensity Of Competitor's
 - 4.1.4 Threat Of New Entrants
 - 5 Global UTI Drugs Market, By Drug Class
- Continue.....

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Related Report

Global Dental Suture Market, By Type - Forecast to 2027. Know more about this report @ <https://www.marketresearchfuture.com/statistical-reports/global-dental-suture-market-type-3096>

Single User PDF: USD 299

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/385852990>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.